 |
市场调查报告书
商品编码
1122402
骨髓增生异常综合征治疗市场：按代理、管理途径、分销渠道、地区 - 规模、份额、前景和机会分析，2022-2030Myelodysplastic Syndrome Treatment Market, by Drug, by Route of Administration, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030 |
||||||
价格
简介目录
骨髓增生异常综合征是一组癌症，其中骨髓中的未成熟血细胞未成熟并成为健康血细胞。根据血细胞和骨髓的某些变化来诊断骨髓增生异常综合征的类型。骨髓增生异常综合征 (MDS) 是一种罕见的血癌，其中没有足够的健康血细胞。也称为骨髓增生异常综合征。 MDS 有多种类型。在 MDS 中，骨髓中的一些细胞异常（发育异常）并且难以製造新的血细胞。这些骨髓细胞形成的一些血细胞是有缺陷的。有缺陷的细胞通常比正常细胞死亡得更快，身体会破坏异常血细胞，导致正常血细胞短缺。骨髓增生异常综合征最常见的发现是缺乏红细胞（贫血），但许多不同的细胞类型都会受到影响。治疗相关的 MDS 是骨髓增生异常综合征的一种亚型。它是由先前癌症的化学疗法或放射疗法引起的。在美国，骨髓增生异常综合征和与治疗相关的骨髓增生异常综合征的新诊断正在增加。这是因为老年人口正在增加，癌症治疗后人们的寿命更长。
市场动态
阿扎胞甘在北美、拉丁美洲、欧洲、亚太地区、非洲等关键地区的上市和批准数量不断增加，预计将在预测期内推动骨髓增生异常综合征治疗市场阿扎胞甘部分的增长。例如，2018年2月，百济神州生物技术公司宣布VIDAZ（注射用阿扎胞甘）在中国上市。 VIDAZA 在中国已获批用于中/高危骨髓增生异常综合征（MDS）、20-30% 成髓细胞的急性髓细胞白血病（AML）和慢性粒单核细胞白血病（CMML）患者。在中国，它由百济神州根据新基公司（製药公司）的独家许可进行销售。
本研究的主要特点
- 本报告对全球骨髓增生异常综合征 (MDS) 治疗市场进行了深入分析，揭示了以 2021 年为基准年的预测期内（2022-2030 年）的市场规模和復合年增长率 (CAGR%)。 ) 提供。
- 它揭示了不同细分市场的潜在收入机会，并为该市场概述了一个有吸引力的投资建议矩阵。
- 它还提供关键见解，例如市场驱动因素、限制因素、机会、新产品发布或批准、市场趋势、区域前景以及主要参与者采用的竞争策略。
- 根据公司亮点、产品组合、关键亮点、业绩和战略等参数，介绍了全球骨髓增生异常综合征 (MDS) 治疗市场中的主要参与者的概况。
- 本研究涉及的主要公司包括 Celgene Corporation、Otsuka Pharmaceutical Co., Ltd.、Teva Pharmaceutical Industries Ltd.、Sun Pharmaceutical Industries Limited、Dr. Reddy's Laboratories Ltd.、Mylan NV、Cipla Limited、Acceleron Pharma, Inc .、Area Therapeutics、FibroGen Inc.、Onconova Therapeutics Inc. 和 Geron。
- 本报告中的见解将使营销人员和企业高管能够就未来的产品发布、类型升级、市场扩张和营销策略做出明智的决策。
- 全球骨髓增生异常综合征 (MDS) 治疗市场报告迎合了该行业的各种利益相关者，包括投资者、供应商、产品製造商、分销商、新进入者和财务分析师。1.
- 利益相关者可以通过用于分析全球骨髓增生异常综合征 (MDS) 治疗市场的各种战略矩阵来促进他们的决策。
内容
第 1 章目的和先决条件
- 调查目的
- 先决条件
- 缩写说明
第二章市场展望
- 举报内容
- 市场定义和范围
- 执行摘要
- 市场快照：按药物分类
- 按管理途径划分的市场概况
- 市场快照：按分销渠道
- 市场概况：按地区划分
- 连贯的机会图 (COM)
第 3 章市场动态、法规和趋势分析
- 市场动态
- 驱动程序
- 约束因素
- 市场机会
- 影响分析
- 市场趋势
- 近期趋势
- 收购和合作方案
- 技术概述
- 监管场景
- 价格分析
- PEST 分析
第 4 章全球骨髓增生异常综合征 (MDS) 治疗市场 - 冠状病毒 (COVID-19) 大流行的影响
- 整体影响
- 政府举措
- COVID-19 对市场的影响
第 5 章。2017-2030 年按代理分列的全球骨髓增生异常综合征 (MDS) 治疗市场
- 来那度胺
- 地西他滨
- 阿扎胞甘
- 第 3 阶段药物
第 6 章。按给药途径分列的骨髓增生异常综合征 (MDS) 治疗的全球市场：2017-2030 年
- 注入
- 口语
第 7 章。全球骨髓增生异常综合征 (MDS) 治疗市场：按分销渠道，2017-2030 年
- 医院药房
- 零售药房
- 在线药店
第 8 章。2017-2030 年按地区分列的全球骨髓增生异常综合征 (MDS) 治疗市场
- 北美
- 美国
- 加拿大
- 拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲地区
- 欧洲
- 英国
- 德国
- 意大利
- 法国
- 西班牙
- 俄罗斯
- 其他欧洲
- 亚太地区
- 中国
- 印度
- 日本
- 东盟
- 澳大利亚
- 韩国
- 其他亚太地区
- 中东
- 海合会
- 以色列
- 其他中东
- 非洲
- 北非
- 中非
- 南非
第 9 章竞争格局
- 热图分析
- 公司简介
- Celgene Corporation
- Otsuka Pharmaceutical Co., Ltd.
- Teva Pharmaceutical Industries Ltd.
- Sun Pharmaceutical Industries Limited
- Dr. Reddy's Laboratories Ltd.
- Mylan NV
- Cipla Limited
- Acceleron Pharma, Inc.
- Aprea Therapeutics
- FibroGen Inc.
- Onconova Therapeutics Inc.
- Geron
第 10 章
- 参考资料
- 调查方法介绍
- 关于出版商
简介目录
Product Code: CMI775
Myelodysplastic syndromes are a group of cancers in which immature blood cells in the bone marrow do not mature or become healthy blood cells. The different types of myelodysplastic syndromes are diagnosed based on certain changes in the blood cells and bone marrow. Myelodysplastic syndromes (MDS) are a type of rare blood cancers where don't have enough healthy blood cells. It is also known as myelodysplasia. There are several different types of MDS. In MDS, some of the cells in the bone marrow are abnormal (dysplastic) and have problems making new blood cells. Several of the blood cells formed by these bone marrow cells are defective. Defective cells often die earlier than normal cells, and the body also destroys some abnormal blood cells, leaving the person without enough normal blood cells. Different cell types can be affected, although the most common finding in Myelodysplastic syndromes is a shortage of red blood cells (anemia). Therapy-related MDS is a subtype of Myelodysplastic syndromes. It is caused by treatment with chemotherapy or radiation therapy for a previous cancer. In the U.S., the number of new diagnoses of Myelodysplastic syndromes and therapy-related Myelodysplastic syndromes are both rising. This is because older people make up a growing segment of the population and people now live longer after treatment for cancer.
Market Dynamics
Increasing launch and approval of Azacitidine in key regions namely North America, Latin America, Europe, Asia Pacific, and Africa etc. is expected to drive growth of Azacitidine segment of the myelodysplastic syndrome treatment market over the forecast period. For instance, in February 2018, BeiGene, Ltd. Biotechnology Company announced the commercial availability of VIDAZ (azacitidine for injection) in China. VIDAZA is approved in China for patients with intermediate-2 / high-risk myelodysplastic syndrome (MDS), acute myeloid leukemia (AML) with 20-30% bone marrow blasts, and chronic myelomonocytic leukemia (CMML). It is marketed in China by BeiGene under an exclusive license from Celgene Corporation (Pharmaceutical Company).
Key features of the study:
- This report provides an in-depth analysis of the global myelodysplastic syndrome (MDS) treatment market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global myelodysplastic syndrome (MDS) treatment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Celgene Corporation, Otsuka Pharmaceutical Co., Ltd. Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Limited, Dr. Reddy's Laboratories Ltd., Mylan NV, Cipla Limited, Acceleron Pharma, Inc., Aprea Therapeutics, FibroGen Inc., Onconova Therapeutics Inc., and Geron.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global myelodysplastic syndrome (MDS) treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts1
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global myelodysplastic syndrome (MDS) treatment market
Detailed Segmentation:
- Global Myelodysplastic Syndrome (MDS) Treatment Market, By Drug :
- Lenalidomide
- Decitabine
- Azacitidine
- Phase 3 Drugs
- Global Myelodysplastic Syndrome (MDS) Treatment Market, By Route of Administration:
- Injection
- Oral
- Global Myelodysplastic Syndrome (MDS) Treatment Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Myelodysplastic Syndrome (MDS) Treatment Market, By Region:
- North America
- By Country
- U.S.
- Canada
- Latin America
- By Country
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- By Country
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- By Country
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- By Country
- GCC
- Israel
- Rest of Middle East
- Africa
- By Country
- South Africa
- Central Africa
- North Africa
- North America
- Company Profiles
- Celgene Corporation
- Company Highlights
- Products Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Otsuka Pharmaceutical Co., Ltd.
- Teva Pharmaceutical Industries Ltd.
- Sun Pharmaceutical Industries Limited
- Reddy's Laboratories Ltd.
- Mylan NV
- Cipla Limited
- Acceleron Pharma, Inc.
- Aprea Therapeutics
- FibroGen Inc.
- Onconova Therapeutics Inc.
- Geron
- Celgene Corporation
"*" marked represents similar segmentation in other categories in the respective section.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Drug
- Market Snapshot, By Route of Administration
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Market Trends
- Recent Developments
- Acquisitions and Partnerships Scenario
- Technology Overview
- Regulatory Scenario
- Pricing Analysis
- PEST Analysis
4. Global Myelodysplastic Syndrome (MDS) Treatment Market- Impact of Coronavirus (Covid-19) Pandemic
- Overall Impact
- Government Initiatives
- COVID-19 Impact on the market
5. Global Myelodysplastic Syndrome (MDS) Treatment Market, By Drug, 2017 - 2030, (US$ Million)
- Overview
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 - 2030
- Segment Trends
- Lenalidomide
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
- Decitabine
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
- Azacitidine
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
- Phase 3 Drugs
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
6. Global Myelodysplastic Syndrome (MDS) Treatment Market, By Route of Administration, 2017 - 2030, (US$ Million)
- Overview
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 - 2030
- Segment Trends
- Injection
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
- Oral
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
7. Global Myelodysplastic Syndrome (MDS) Treatment Market, By Distribution Channel, 2017 - 2030, (US$ Million)
- Overview
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 - 2030
- Segment Trends
- Hospital Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
- Retail Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
- Online Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
8. Global Myelodysplastic Syndrome (MDS) Treatment Market, By Region, 2017 - 2030, (US$ Million)
- Introduction
- Market Share Analysis, By Region, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, For Regions, 2017-2030
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2017 - 2030, (US$ Million)
- North Africa
- Central Africa
- South Africa
9. Competitive Landscape
- Heat Map Analysis
- Company Profiles
- Celgene Corporation
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Otsuka Pharmaceutical Co., Ltd.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Teva Pharmaceutical Industries Ltd.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Sun Pharmaceutical Industries Limited
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Dr. Reddy's Laboratories Ltd.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Mylan NV
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Cipla Limited
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Acceleron Pharma, Inc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Aprea Therapeutics
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- FibroGen Inc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Onconova Therapeutics Inc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Geron
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Analyst Views
10. Section
- References
- Research Methodology
- About Us
